Brian Helfand, MD, PhD, NorthShore University
Articles
Prostate Cancer: Clinical Implications From the EMPIRE-1 Trial
Brian Helfand, MD, PhD, NorthShore University;Steven Finkelstein, MD, FACRO, Florida Cancer Affiliates
September 20th 2021Drs Brian Helfand and Steven Finkelstein share key takeaways and clinical pearls from the phase 2/3 EMPIRE-1 trial for prostate cancer.
Phase 2/3 EMPIRE-1 Trial in Prostate Cancer
Brian Helfand, MD, PhD, NorthShore University;Steven Finkelstein, MD, FACRO, Florida Cancer Affiliates
September 13th 2021Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, review results from the phase 2/3 EMPIRE-1 trial examining the use of ¹⁸F-fluciclovine-PET/CT imaging to guide postprostatectomy salvage radiotherapy for prostate cancer.
Latest Updated Articles
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Published: September 2nd 2014 | Updated: October 24th 2024
Tumor Found Near Achilles Tendon
Published: July 16th 2011 | Updated: October 24th 2024
Neonate With a Soft, Yellowish-Colored Plaque on the Temple
Published: May 17th 2013 | Updated: October 24th 2024
Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
